Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2023 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Feb 10, 2023
Slide 1: Exchange cover letter on Q3FY23 results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 10th February, 2023 The Corpo
Slide 2: Press Release: Alkem reports Q3FY23 and 9MFY23 results
<a> ALKEM ALKEM LABORATORIES LTD. Regd, Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem reports
Slide 3: Operational Highlights: Domestic Business
<a> ALKEM ALKEM LABORATORIES LTD. Regd, Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Operational Highlights Domes
Slide 4: International Business
<a> ALKEM ALKEM LABORATORIES LTD. Regd, Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 International Business In Q3
Slide 5: Q3FY23 and 9MFY23 Conference Call details
<a> ALKEM ALKEM LABORATORIES LTD. Regd, Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q3FY23 and 9MFY23 Conference
Slide 6: Investor Presentation Q3FY23
Investor Presentation Q3FY23 February 10, 2023
Slide 7: Safe Harbor Statement
Safe Harbor Statement <a> ALKEM This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of Q3FY23 and 9MFY23
Key Highlights of Q3FY23 and 9MFY23 <a> ALKEM • Revenue from Operation grew 16.1% YoY during the quarter, with EBITDA margin of 19.7% and Net Profit margin of 15.0% • India Business: As per IQVIA, Company’s sales in Q3FY23 registered growth of 16.7% YoY compared to IPM growth of 10.0% YoY • Consiste
Slide 9: Key Financial Highlights – Q3FY23 (Consolidated)
Key Financial Highlights – Q3FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 19,922 18,156 30,409 26,190 r----- ~ Q3FY22 Q3FY23 International sales 9,928 7,710 Q3FY22 Q3FY23 Q3FY22 Q3FY23
Slide 10: Key Financial Highlights – Q3FY23 (Consolidated)
Key Financial Highlights – Q3FY23 (Consolidated) <a> ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 17,920 5,990 16,223 0 ,,o/o 4,985 r - - - - - - -~ [..._ _______) 61.9% 58.9% [..._ _______) 19.0% 19.7% Q3FY22 Q3FY23 Q3FY22 Q3FY23 PBT PAT (after Minority Interest)
Slide 11: Key Financial Highlights – 9MFY23 (Consolidated)
Key Financial Highlights – 9MFY23 (Consolidated) <a> ALKEM All figures in ₹ mn Particulars (₹ mn) 9MFY23 9MFY22 YoY growth Revenue from Operations 86,967 81,503 6.7% Gross Profit 50,453 50,014 0.9% Gross Profit margin 58.0% 61.4% EBITDA 12,562 17,157 -26.8% EBITDA margin 14.4% 21.1% PBT 10,931 16,01
Slide 12: India Business
<a> India Business ALKEM India Business: Q3FY23 Sales of ₹ 19,922 million (9.7% YoY growth) • India sales contributed 66.7% to total sales in Q3FY23 • As per IQVIA, In Q3FY23, the Company’s secondary sales grew by 16.7% compared to IPM growth of 10.0% YoY. • Outperformance in acute therapies was mai
Slide 13: Secondary Sales Performance
Secondary Sales Performance <a> ALKEM Market beating performance across major therapeutic segments in Q3FY23 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 21.0% 14.0% 11.3% 12.8% 12.0% 10.2% 8.1% 7.9% - Alkem sales growth YoY1,2
Slide 14: US Business
US Business <a> ALKEM US Business: Q3FY23 Sales of ₹ 7,612 million (32.8% YoY growth) • US sales contributed 25.5% to total sales in Q3FY23 • During the quarter, the US business registered sequential growth of 26.0% over Q2FY23 • In Q3FY23, the Company filed 2 ANDAs with the US FDA and received 3 ap
Slide 15: US Business: Update on US FDA inspections
US Business <a> ALKEM Update on US FDA inspections Facility Capability Last inspection Status post last inspection St. Louis (US) Formulations November 2022 Inspection is closed. EIR# received in December 2022 Bioequivalence Taloja (India) October 2022 Successfully closed inspection without any obse
Slide 16: Other International Business
<a> Other International Business ALKEM Other International Business: Q3FY23 Sales of ₹ 2,316 million (17.1% YoY growth) • Other International Market sales contributed 7.8 % to total sales in Q3FY23 • The Company has presence in Latin America, Australia, Europe, South East Asia, Africa and CIS. • Gro
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern <a> ALKEM Shareholding pattern as on December 31, 2022 Non-Institution, 21.99% Promoter & Promoter Group, 57.16% Institution, 20.85% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Publi
Slide 18: Thank You
<a> ALKEM Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com